At this year’s Morningstar Investment Conference in Chicago, Morningstar equity researchers will share their insights on the ...

The actress shares her weight loss journey, revealing she hopes to shed 40 pounds with Ozempic after struggling with body ...

Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing weight-loss drugs.

FAIR Health data released this month showed more than 2% of adult patients now take a GLP-1 drug to treat overweight or obesity. Among all adult patients, the percentage who had an overweight or ...

Semaglutide injections are helping you lose weight-but if yours isn't FDA-approved (and a lot of them aren't), it could be ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

These included the sale of its BioReference laboratory testing businesses, which focused on oncology and oncology-related ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared ...

Patients who took a GLP-1 drug fared better than those in a control group at keeping their blood glucose levels in a healthy ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...